A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination With Rituximab-CHOP in Patients With Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)
Latest Information Update: 14 May 2025
At a glance
- Drugs Vorinostat (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 20 Mar 2025 Planned End Date changed from 7 Mar 2025 to 6 Mar 2026.
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 06 Jun 2012 Planned end date changed from 1 Jul 2011 to 1 Dec 2015 as reported by ClinicalTrials.gov.